NCT00251004 arm group 7a3f863171da4aba04cd02da2b3a970d [clinicaltrials_resource:NCT00251004/arm-group/7a3f863171da4aba04cd02da2b3a970d]
Mycophenolic Acid (MPA) [clinicaltrials_resource:0d0ba7492e861de5df5b718f9495d1e9]Corticosteroids [clinicaltrials_resource:2e40285d72c4f72033b40fae9122b906]Basiliximab [clinicaltrials_resource:37bc4403f2e69d0422ececbfd595d37f]Cyclosporine A (CsA) [clinicaltrials_resource:77e70ada8c4813da41ed1fd351511ce5]clinicaltrials:NCT00251004
arm group [clinicaltrials_vocabulary:arm-group]
NCT00251004 arm group 7a3f863171da4aba04cd02da2b3a970d [clinicaltrials_resource:NCT00251004/arm-group/7a3f863171da4aba04cd02da2b3a970d]
Bio2RDF identifier
NCT00251004/arm-group/7a3f863171da4aba04cd02da2b3a970d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 3f863171da4aba04cd02da2b3a970d
description [clinicaltrials_vocabulary:description]
1.44 g Mycophenolic Acid (two ...... ed according to local therapy.
identifier
clinicaltrials_resource:NCT00251004/arm-group/7a3f863171da4aba04cd02da2b3a970d
title
NCT00251004 arm group 7a3f863171da4aba04cd02da2b3a970d
@en
type
label
NCT00251004 arm group 7a3f8631 ...... f863171da4aba04cd02da2b3a970d]
@en